These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 1726450

  • 1. Hodgkin's disease. A historical perspective.
    Avilés A, Díaz-Maqueo JC, Torras V, Ayala JR, Cortés HD.
    Arch Invest Med (Mex); 1991; 22(1):27-33. PubMed ID: 1726450
    [Abstract] [Full Text] [Related]

  • 2. Hodgkin's disease: summary of twenty years' experience.
    Mazza P, Bocchia M, Zinzani PL, Fiacchini M, Gherlinzoni F, Bandini G, Bendandi M, Frezza GP, Neri S, Barbieri E.
    Haematologica; 1992; 77(6):487-93. PubMed ID: 1283856
    [Abstract] [Full Text] [Related]

  • 3. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M, Ditonno P, Lorusso V, Timurian A, Pellecchia A, Brandi M, Berardi F, Marzullo F.
    Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
    [Abstract] [Full Text] [Related]

  • 4. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM.
    Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
    [Abstract] [Full Text] [Related]

  • 5. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL, Fiacchini M, Mazza P, Gherlinzoni F, Bocchia M, Tura S.
    Haematologica; 1991 Jun; 76(4):305-10. PubMed ID: 1724437
    [Abstract] [Full Text] [Related]

  • 6. Hodgkin's disease: controversies and challenges for the future.
    Tura S, Canellos G, Goldstone A, Longo D, McMillan A, Urba W, Zinzani PL.
    Haematologica; 1991 Jun; 76(4):263-79. PubMed ID: 1724436
    [No Abstract] [Full Text] [Related]

  • 7. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):765-81. PubMed ID: 15183480
    [Abstract] [Full Text] [Related]

  • 8. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.
    Haematologica; 1998 Sep 01; 83(9):812-23. PubMed ID: 9825578
    [Abstract] [Full Text] [Related]

  • 9. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 10. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
    Brusamolino E, Lazzarino M, Morra E, Inverardi D, Merante S, Castelli G, Canevari A, Dornini G, Bernasconi C.
    Haematologica; 1989 May 01; 74(2):173-9. PubMed ID: 2473013
    [Abstract] [Full Text] [Related]

  • 11. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
    Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
    [Abstract] [Full Text] [Related]

  • 12. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P.
    Eur J Cancer; 2005 May 15; 41(7):998-1006. PubMed ID: 15862748
    [Abstract] [Full Text] [Related]

  • 13. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, Ternberg JL, Behm FG, Wharam MD, Chauvenet AR.
    J Clin Oncol; 1997 Aug 15; 15(8):2769-79. PubMed ID: 9256118
    [Abstract] [Full Text] [Related]

  • 14. Pediatric Hodgkin's disease.
    Oliapuram Jose B, Koerner P, Bertolone S, Patel CC, Spanos WJ, Paris KJ, Silverman CL, Yashar CM.
    J Ky Med Assoc; 2004 Mar 15; 102(3):104-6. PubMed ID: 15067795
    [Abstract] [Full Text] [Related]

  • 15. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Oliveira JS.
    Ann Hematol; 2009 Jul 15; 88(7):633-7. PubMed ID: 18998131
    [Abstract] [Full Text] [Related]

  • 16. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
    Santoro A, Viviani S, Villarreal CJ, Bonfante V, Delfino A, Valagussa P, Bonadonna G.
    Cancer Treat Rep; 1986 Mar 15; 70(3):343-8. PubMed ID: 2420444
    [Abstract] [Full Text] [Related]

  • 17. [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
    Wang WH, Li YX, Song YW, Jin J, Liu YP, Wang SL, Zhou LQ, Liu XF, Yu ZH, Han JZ.
    Zhonghua Zhong Liu Za Zhi; 2006 Mar 15; 28(3):218-21. PubMed ID: 16875611
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the risk of solid tumor following Hodgkin's disease.
    Maurizi Enrici R, Anselmo AP, Osti MF, Santoro M, Tombolini V, Mandelli F, Biagini C.
    Haematologica; 1997 Mar 15; 82(1):57-63. PubMed ID: 9107084
    [Abstract] [Full Text] [Related]

  • 19. [Improved survival rates in Hodgkin's disease].
    Hayabuchi N, Jingu K, Miyoshi M, Hirata H, Masuda K, Shibuya T, Nishimura J, Komiyama S, Ishii E, Kikuchi M.
    Gan No Rinsho; 1988 Apr 15; 34(5):698-704. PubMed ID: 2455073
    [Abstract] [Full Text] [Related]

  • 20. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F, Busia A, Villani M, Laffranchi A, Viviani S, Bonfante V.
    Anticancer Res; 2009 Feb 15; 29(2):777-83. PubMed ID: 19331235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.